This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytokinetics Ends Cancer Deal With GlaxoSmithKline

NEW YORK (AP) ¿ Cytokinetics Inc. said Wednesday it ended a deal with GlaxoSmithKline PLC that had focused on developing a potential cancer treatment, sending shares sharply lower in after-hours trading.

Cytokinetics said, effective Feb. 28, all rights for the potential cancer treatment GSK-923295 will revert back to the biotechnology company. GlaxoSmithKline will still be responsible for completing an ongoing Phase I clinical trial.

The decision is part of Cytokinetics' plan to focus its internal research and development efforts on muscle function and related therapies, the company said.

"In our industry, and especially in these challenging times, it is increasingly important to remain focused and execute on a core business strategy," said President and CEO Robert I. Blum, in a statement.

"At Cytokinetics, we believe our best opportunities are rooted in our multiple programs directed to the biology of muscle function," he said. "Today's announcement, combined with our company's previously disclosed decisions to discontinue oncology research and phase out related development activities and spending, is further evidence of our commitment to this strategy."

Shares of Cytokinetics fell 33 cents, or 10.5 percent, to $2.80 in aftermarket electronic trading. The stock had gained 7 cents to close the regular session at $3.13.

Shares of GlaxoSmithKline fell 46 cents to close the regular trading session at $41.59.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CYTK $8.16 -2.86%
GSK $42.35 -1.83%
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs